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Abstract  
Background: Optimisation of drug therapy is important in the older population and may be facilitated by medication assessment tools 
(MATs).  
Objective: The purpose of the study was to evaluate whether appropriateness of drug therapy and clinical pharmacist intervention 
documentation improved following implementation of a previously developed MAT for the long-term management of atrial fibrillation 
(MAT-AF).  
Methods: Adherence to MAT-AF review criteria and clinical pharmacist intervention documentation was assessed by the researcher 
pre-MAT implementation in 150 patients aged ≥60 years admitted to a rehabilitation hospital with a diagnosis of atrial fibrillation. 
MAT-AF was introduced as a clinical tool in the hospital for identification of pharmaceutical care issues in atrial fibrillation patients. 
Adherence to MAT-AF and pharmacist intervention documentation were assessed by the researcher post-MAT implementation for a 
further 150 patients with the same inclusion criteria. Logistic regression analysis and measurement of odds ratio was used to identify 
differences in adherence to MAT-AF pre- and post-MAT implementation. The differences between two population proportions z-test 
was used to compare pharmacist intervention documentation pre- and post-MAT implementation. 
Results: Adherence to MAT-AF criteria increased from 70.9% pre-implementation to 89.6% post-implementation. MAT-AF 
implementation resulted in a significant improvement in prescription of anticoagulant therapy (OR 4.07, p<0.001) and monitoring of 
laboratory parameters for digoxin (OR 10.40, p<0.001). Clinical pharmacist intervention documentation improved significantly post-
implementation of MAT-AF (z-score 20.249, p<0.001). 
Conclusions: Implementation of MAT-AF within an interdisciplinary health care team significantly improved the appropriateness of 
drug therapy and pharmacist intervention documentation in older patients with atrial fibrillation.   
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INTRODUCTION 
Extensive literature has confirmed the value of clinical 
pharmacist intervention in improving the appropriateness 
of drug treatment in older patients.1-5 As the proportion of 
older persons continues to increase, the role of the clinical 
pharmacist as a member of a multi-professional team is 
becoming more crucial for optimisation of drug therapy in 
this patient population.4 Documentation of pharmacist 
interventions provides a record which is important for 
continuity of care, accountability of pharmacist services 
and quality assurance.6,7 
Several medication review tools have been designed to 
enhance appropriate prescribing in older patients.8 The 
medication assessment tool MAT-AF is an innovative and 
validated tool, previously developed by this research group, 
for the long-term management of atrial fibrillation (AF) in 
older persons.9 MAT-AF incorporates criteria for assessing 
appropriateness of drug therapy whilst applying the clinical 
considerations required in managing drug therapy for AF 
(refer to supplementary material). Review criteria in MAT-
AF are composed of a qualifying statement and a standard, 
sectioned into antithrombotic, rate control and rhythm 
control therapy. Content validity was tested by an expert 
group using a Delphi technique and consensus obtained for 
all final criteria. Inter- and intra-observer reliability and 
feasibility was demonstrated. An application guide for 
consistent interpretation and application of the MAT was 
compiled.9 
MAT-AF was developed on the basis that AF is associated 
with substantial morbidity and mortality and requires 
consideration of management recommendations focusing 
on thromboembolic risk reduction, rate control and rhythm 
control.10-13 MAT-AF considers guidelines on the use of 
antithrombotic agents endorsed for the prevention of 
thromboembolism namely warfarin and direct oral 
anticoagulants (DOACs).10-13 Recent guidelines recommend 
that a DOAC be used preferentially to warfarin on the basis 
of strong evidence of a lower risk of intracranial 
haemorrhage, although cost effectiveness remains a 
debatable issue considering the high cost of DOACs.12-14  
Rate control is a key component in the management of AF 
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patients. Beta-blockers, nondihydropyridine calcium 
channel blockers or digoxin are recommended as suitable 
first-line options.13 When monotherapy is insufficient to 
achieve rate control, digoxin is recommended in 
combination with a beta-blocker or with a 
nondihydropyridine calcium channel blocker.10-13 
Amiodarone should be considered when other agents are 
unsuccessful or contraindicated.10,12,13 Monitoring of serum 
digoxin levels, renal function, thyroid function and 
electrolytes is recommended for safe use of digoxin.15 Liver, 
thyroid, ophthalmic and pulmonary monitoring is 
recommended with amiodarone treatment.16 Restoring and 
maintaining sinus rhythm is another aspect of AF 
management.10-13 Clinical evidence has demonstrated that 
both rhythm and rate control strategies have resulted in 
similar outcomes.17,18 Long-term antiarrhythmic agents 
should be commenced judiciously after consideration of 
the extent of symptoms and potential for adverse drug 
reactions. A rate control strategy is often preferred in older 
persons.10,13 
The purpose of the study was to evaluate whether 
implementation of MAT-AF in clinical practice contributes 
to improving the appropriateness of drug therapy and 
clinical pharmacist intervention documentation. Adherence 
to MAT-AF review criteria was used to measure 
appropriateness of drug therapy and to determine whether 
a pharmacist intervention was generated. 
 
METHODS 
The study setting was Karin Grech Hospital in Malta, a 280-
bed hospital specialising in rehabilitation of older patients.  
Clinical pharmacists complete a paper-based pharmacy 
patient profile for each patient at the hospital. 
Pharmaceutical care issues, interventions and outcomes 
are documented by the pharmacist on the profile in daily 
clinical practice.  
Adherence to MAT-AF criteria was assessed by the 
researcher prior to MAT implementation by application of 
the tool to 150 patients admitted for rehabilitation.9 
Inclusion criteria were a diagnosis of AF and age ≥60 years 
while transfer of the patient to acute care and death were 
considered as exclusion criteria. The MAT was applied by 
the researcher to patients consecutively at discharge from 
March to September 2016. The pharmacy patient profile of 
each patient was reviewed to determine whether care 
issues generated by MAT application resulted in a 
documented intervention by the clinical pharmacist. The 
pharmaceutical care issues were classified in terms of a set 
of care issue types defined in the hospital standard 
operating procedure for patient profiling.19 
The use of MAT-AF as a clinical tool was introduced by the 
researcher to the nine clinical pharmacists at the hospital. 
Following a training period of two weeks, the pharmacists 
used the tool in practice by applying the MAT criteria to 
patients admitted with AF for identification of 
pharmaceutical care issues which were to be followed by 
intervention and documentation.  
Adherence to MAT-AF and clinical pharmacist intervention 
documentation were assessed post-MAT implementation 
for a further 150 patients admitted to the hospital with the 
same inclusion criteria. MAT-AF was applied by the 
researcher to audit patients consecutively at discharge 
from November 2016 to May 2017.  
The study protocol was approved by the Karin Grech 
Hospital Research Committee and the University of Malta 
Research Ethics Committee. 
Statistical analysis 
Data analysis was conducted using IBM SPSS® Statistics 
version 24. Descriptive statistics were generated for the 
study population in the pre- and post-implementation 
Table 1. Patient characteristics for the study population pre- and post-implementation of MAT-AF  
(n=150) Pre-implementation Post-implementation 
Gender (n)     
male 54 (36.0%) 44 (29.3%) 
female 96 (64.0%) 106 (70.7%) 
Age (years)     
mean (SD) 81.7 (7.6) 82.7 (6.4) 
min, max 60 97 63 97 
≥75 years (n) 127 (84.7%) 134 (89.3%) 
Atrial fibrillation (n)     
paroxysmal 54 (36.0%) 67 (44.7%) 
persistent 12 (8.0%) 11 (7.3%) 
permanent 84 (56.0%) 72 (48.0%) 
Comorbidities (n)     
heart failure 93 (62.0%) 92 (61.3%) 
hypertension 108 (72.0%) 112 (74.7%) 
diabetes 48 (32.0%) 59 (39.3%) 
stroke/TIA/thromboembolism 51 (34.0%) 50 (33.3%) 
vascular disease* 52 (34.7%) 53 (35.3%) 
anaemia 68 (45.3%) 82 (54.7%) 
chronic kidney disease** 103 (68.7%) 116 (77.3%) 
CHA2DS2VASc score ≥1 (n)*** 149 (99.3%) 150 (100.0%) 
HAS-BLED score (0-9)      
mean (SD) 2.0 (0.8) 2.1 (0.8) 
min, max 1 4 0 4 
*acute coronary syndrome or peripheral arterial disease (including revascularisation), **creatinine clearance 
<60ml/min, ***excluding gender, TIA – transient ischaemic attack 
Data for pre-implementation phase reported by Gauci et al.
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phases. Characteristics of the patient populations were 
compared by the independent samples t-test for 
quantitative variables and the differences between two 
population proportions z-test for qualitative variables. 
Adherence to MAT criteria was computed by the sum of the 
‘adherence’ and ‘justified non-adherence’ responses 
expressed as a percentage of the applicable criteria. 
Criterion responses which were not applicable or which had 
insufficient data for the qualifying statement were 
excluded.9  Logistic regression analysis and measurement of 
odds ratio was used to identify differences in adherence to 
MAT-AF pre- and post-MAT implementation. The 
differences between two population proportions z-test was 
used to compare pharmacist intervention documentation 
pre- and post-MAT implementation. The Pearson chi-
square test was used to assess the relationship between 
prescription of anticoagulation with patient age and 
CHA2DS2VASc score.
20 
 
RESULTS  
Patient population characteristics in the pre- and post-
implementation phases of MAT-AF application are 
Table 2. Adherence to applicable criteria of MAT-AF pre- and post-implementation 
Criterion focus 
Pre-implementation Post-implementation 
Odds Ratio 
[95% CI] 
p-value 
Applicable 
cases 
Adherence 
Applicable 
cases 
Adherence 
n (%) n (%) n (%) n (%) 
Antithrombotic therapy       
1 
No antithrombotic therapy if CHA2DS2VASc 
score 0* 
1 (0.7) 1 (100) 0 (0) 0 (0) - - 
2 
Prescription of oral anticoagulant if 
CHA2DS2VASc score ≥1* 
149 (99.3) 105 (70.5) 150 (100) 136 (90.7) 
4.07 
[2.12 – 7.82] 
<0.001 
3 
Prescription of direct oral anticoagulant at 
recommended dose if creatinine clearance 
≥50mL/min 
5 (3.3) 4 (80.0) 7 (4.7) 6 (85.7) 
1.50 
[0.07 – 31.58] 
0.794 
4 
Prescription of direct oral anticoagulant at 
lower dose or warfarin if creatinine 
clearance between 15-49ml/min 
47 (31.3) 47 (100) 58 (38.7) 55 (94.8) - - 
5 
Prescription of warfarin if creatinine 
clearance <15ml/min 
1 (0.7) 1 (100) 1 (0.7) 1 (100) - - 
Rate control therapy       
6 
Prescription of beta-blocker, non-
dihydropyridine calcium channel blocker 
and/or digoxin 
97 (64.7) 82 (84.5) 95 (63.3) 92 (96.8) 
3.92 
[1.06 – 14.54] 
0.041 
7 
Cardiology referral/follow up if non-
dihydropyridine calcium channel blocker and 
contraindicated/not  tolerated 
1 (0.7) 0 (0) 0 (0) 0 (0) - - 
8 
Prescription of beta-blocker and/or digoxin if 
heart failure with left ventricular ejection 
fraction <40% 
12 (8.0) 12 (100) 7 (4.7) 7 (100) - - 
9 
Monitoring of renal and thyroid function, 
serum electrolytes with digoxin and within 
range 
53 (35.3) 27 (50.9) 59 (39.3) 54 (91.5) 
10.40 
[3.59 – 30.10] 
<0.001 
10 
Monitoring of serum digoxin level if at risk of 
high serum concentration and within range 
23 (15.3) 17 (73.9) 23 (15.3) 20 (87.0) 
2.35 
[0.51 – 10.86] 
0.273 
11 
Prescription of amiodarone for additional 
rate control or contraindication/intolerance 
to other agents 
1 (0.7) 0 (0) 0 (0) 0 (0) - - 
12a 
Monitoring of liver and thyroid function with 
amiodarone and within range 
21 (14.0) 17 (81.0) 16 (10.7) 15 (93.8) 
3.53 
[0.35 – 35.16] 
0.282 
12b 
Monitoring of ophthalmic and pulmonary 
function with amiodarone 
21 (14.0) 0 (0) 16 (10.7) 4 (25.1) - - 
Rhythm control therapy       
13 
Continuation at prescribed dose if 
maintained in sinus rhythm with 
antiarrhythmic agent and well tolerated 
10 (6.7) 7 (70.0) 10 (6.7) 9 (90.0) 
3.86 
[0.33 – 45.57] 
0.284 
14 
Cardiology referral/follow-up if maintained 
in sinus rhythm with antiarrhythmic agent 
and contraindicated/not well tolerated 
3 (2.0) 0 (0.0) 2 (1.3) 0 (0) - - 
15 
Cardiology referral/follow-up if prescribed 
antiarrhythmic agent and not maintained in 
sinus rhythm 
13 (8.7) 5 (38.5) 10 (6.7) 8 (80.0) 
8.00 
[1.13 – 56.79] 
0.038 
Total criteria 458 (19.1) 325 (70.9) 454 (18.9) 407 (89.6)   
*CHA2DS2VASc score excluding gender; Adherence to MAT criteria was calculated by the sum of the ‘adherence’ and ‘justified non-adherence’ 
responses expressed as a percentage of the applicable criteria; Odds ratio not reported for percentage adherence 0 and 100. 
Data for pre-implementation phase reported by Gauci et al.
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presented in Table 1. No significant variation between the 
two study populations was evident (p>0.05). 
Adherence to the 458 applicable criteria was 70.9% before 
MAT-AF implementation.9 In the post-implementation 
phase, adherence to the 454 applicable criteria was 89.6%. 
Application of MAT-AF post-implementation resulted in a 
significant increase in adherence from 70.9% to 89.6%.  
Adherence to MAT-AF criteria for antithrombotic, rate 
control and rhythm control therapy before and after 
implementation is presented in Table 2.  
Table 3. Documented pharmacist interventions for care issues generated by MAT-AF application pre- and post-implementation 
Criterion focus Care issue type 
Pre-implementation Post-implementation 
p-value 
Care issue 
generated 
Intervention 
documented 
Care issue 
generated 
Intervention 
documented 
n n (%) n n (%) 
Antithrombotic therapy  
     
1 No antithrombotic therapy if 
CHA2DS2VASc score 0* 
Unnecessary drug 
0 0 (0) 0 0 (0) - 
2 Prescription of oral anticoagulant if 
CHA2DS2VASc score ≥1* 
Need for additional drug 
60 12 (20.0) 51 48 (94.1) <0.001 
3 Prescription of direct oral 
anticoagulant at recommended dose if 
creatinine clearance ≥50ml/min 
Monitoring need/Dose too low 
5 1 (20.0) 2 1 (50.0) 0.430 
4 Prescription of direct oral 
anticoagulant at lower dose or warfarin 
if creatinine clearance between 15-
49ml/min 
Monitoring need/Dose too high 
1 1 (100) 7 4 (57.1) 0.407 
5 Prescription of warfarin if creatinine 
clearance <15ml/min 
Monitoring need/Improper drug 
selection 
0 0 (0) 0 0 (0) - 
Rate control therapy        
  
6a Monitoring of pulse  Monitoring need 150 0 (0) 150 143 (95.3) <0.001 
6b Prescription of beta-blocker, non-
dihydropyridine calcium channel 
blocker and/or digoxin 
Improper drug selection 
13 1 (7.7) 7 3 (42.9) 0.060 
7 Cardiology referral/follow up if non-
dihydropyridine calcium channel 
blocker and contraindicated/not 
tolerated 
Risk for adverse drug reaction 
1 0 (0) 0 0 (0) - 
8 Prescription of beta-blocker and/or 
digoxin if heart failure with left 
ventricular ejection fraction <40% 
Improper drug selection 
5 0 (0) 3 1 (33.3) 0.503 
9 Monitoring of renal function, thyroid 
function, serum electrolytes with 
digoxin and within range 
Monitoring need 
53 0 (0) 59 50 (84.7) <0.001 
10 Monitoring of serum digoxin level if at 
risk of high serum concentration and 
within range 
Monitoring need 
23 11 (47.8) 23 19 (82.6) 0.013 
11 Prescription of amiodarone for 
additional rate control or 
contraindication/intolerance to other 
agents 
Improper drug selection 
1 0 (0) 0 0 (0) - 
12a Monitoring of liver and thyroid 
function with amiodarone and within 
range 
Monitoring need 
21 10 (47.6) 16 13 (81.3) 0.037 
12b Monitoring of liver and thyroid 
function with amiodarone after 
discharge 
Seamless care need 
21 1 (4.8) 16 5 (31.3) 0.030 
12c Monitoring of ophthalmic and 
pulmonary function  with amiodarone 
Monitoring need/Counselling need 
21 0 (0) 16 8 (50.0) <0.001 
Rhythm control therapy       
13 Continuation at prescribed dose if 
maintained in sinus rhythm with 
antiarrhythmic agent and well 
tolerated 
Need for additional drug/Dose too 
low 
0 0 (0) 1 0 (0) - 
14 Cardiology referral/follow-up if 
maintained in sinus rhythm with 
antiarrhythmic agent and 
contraindicated/not well tolerated 
Risk for adverse drug reaction 
0 0 (0) 2 0 (0) - 
15 Cardiology referral/follow-up if 
prescribed antiarrhythmic agent and 
not maintained in sinus rhythm 
Improper drug selection 
11 0 (0) 8 6 (75.0) <0.001 
Total care issues 386 37 (9.6) 361 301 (83.4) <0.001 
*CHA2DS2VASc score excluding gender 
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MAT-AF implementation resulted in a significant 
improvement in prescription of anticoagulants (OR 4.07, 
p<0.001). The CHA2DS2VASc score did not have a significant 
effect on the prescription of anticoagulation both before 
and after MAT-AF implementation. The prescription of 
anticoagulation according to age range indicated a 
significant decrease in anticoagulation with increasing age 
(chi-square(3)=11.57, p=0.009) pre-MAT implementation. 
Patient age did not have a significant effect on the 
prescription of anticoagulation (chi-square(3)=4.119, 
p=0.249) post-MAT implementation. Recurrent falls or a 
high risk for falls was the most frequent reason for 
omission of anticoagulant therapy in the study population.  
Adherence to appropriate rate control therapy was 84.5% 
before implementation and 96.8% after MAT-
implementation (OR 3.92, p=0.041) (Table 2). Monitoring of 
renal function, thyroid function and serum electrolytes in 
patients receiving digoxin was performed and within limits 
in 50.9% of patients pre-implementation and in 91.5% post-
implementation (OR 10.40, p<0.001). The most common 
deficiency for this criterion was in the request for 
monitoring of serum magnesium. Monitoring of serum 
digoxin levels was indicated due to poor renal function, 
dose of more than 0.0625mg daily or signs and symptoms 
of toxicity. Monitoring was conducted and was within limits 
in 73.9% of patients in whom it was indicated pre-
implementation and in 87.0% post-implementation (OR 
2.35, p=0.273).  
Rhythm control with antiarrhythmic agents was achieved in 
8.3% of patients. Adherence to MAT-AF for cardiology 
referral in patients on antiarrhythmic agents but not 
maintained in sinus rhythm increased from 38.5% pre-
implementation to 80.0% post-implementation (OR 8.00, 
p=0.038) (Table 2). Liver and thyroid function tests in 
patients receiving amiodarone therapy were performed 
and within limits in 81.0% of patients pre-implementation 
and in 93.8% post-implementation (OR 3.53, p=0.282).  
Documented pharmacist interventions for care issues 
generated by MAT-AF application are shown in Table 3. 
MAT-AF application before implementation identified 386 
care issues, 9.6% of which were documented. After MAT-AF 
implementation, 361 care issues were identified and 83.4% 
were documented. The increase in documented pharmacist 
interventions following MAT-AF implementation as a 
clinical tool was significant (z-score 20.249, p<0.001).  
 
DISCUSSION 
Application of MAT-AF pre-implementation revealed 
suboptimal adherence to clinical practice guidelines 
incorporated in the tool. MAT-AF application after 
implementation denoted a significant increase in 
adherence from 70.9% to 89.6% principally in prescription 
of anticoagulation and monitoring of laboratory 
parameters for digoxin. Documentation of clinical 
pharmacist intervention improved significantly post-
implementation of MAT-AF from 9.6% to 83.4%. 
Prior to MAT-AF implementation, adherence to 
anticoagulation was 70.5% despite a high risk of stroke in 
the study population. Analysis of the results indicates that 
there was no correlation between prescription of 
anticoagulation and CHA2DS2VASc score, possibly indicating 
that stroke risk was not being given due consideration. In 
contrast, in a study by Lefebre et al. among octogenarians, 
anticoagulation was positively associated with stroke risk 
score. The HAS-BLED score was applied for assessment of 
bleeding risk to establish justifications for non-
adherence.21,22 The study population prior to MAT-AF 
implementation had a mean HAS-BLED score of 2. The 
principal contributor to the score was the presence of 
anaemia, which was most commonly mild and would merit 
monitoring rather than exclusion of anticoagulation.23 Age 
is a strong predictor for ischaemic stroke in AF patients and 
robust evidence exists to support the use of 
anticoagulation in older persons.20,24-26  In a systematic 
review of studies assessing attitudes of physicians 
regarding anticoagulation for AF, Pugh et al. concluded that 
physicians were reluctant to recommend warfarin for older 
persons in AF.27 Implementation of MAT-AF resulted in oral 
anticoagulants being prescribed irrespective of age.  
Recurrent falls or a high risk of falls were common reasons 
for omission of anticoagulation in the study population, as 
has been stated in other studies.28-30 Although the use of 
anticoagulation in patients at risk of falls requires caution, 
AF guidelines stipulate that anticoagulants should only be 
excluded in patients with severe uncontrolled falls, such as 
epilepsy or advanced multi-system atrophy with backward 
falls.13 Conversely, evidence indicates that stroke risk tends 
to exceed bleeding risk of anticoagulation, even in older 
persons, in patients with cognitive impairment, or in 
patients with frequent falls or frailty.31,32 Documentation of 
clinical pharmacist interventions regarding the appropriate 
prescription of anticoagulation therapy was shown to 
significantly increase following MAT-AF implementation.  
MAT-AF implementation significantly increased monitoring 
of laboratory parameters contributing to the safe use of 
digoxin therapy. A significant increase in clinical pharmacist 
documentation for the recommended monitoring to be 
performed was observed following MAT implementation. 
Rhythm control therapy was only prescribed in a minor 
proportion of patients, which is coherent with evidence 
which has demonstrated that rhythm and rate control 
strategies have resulted in similar outcomes.17,18 MAT-AF 
implementation significantly increased monitoring for 
ophthalmic and pulmonary adverse reactions with 
amiodarone therapy. Although adherence was suboptimal, 
even after MAT-AF implementation, there was increased 
awareness among the clinical pharmacists shown by an 
increase in documentation of the monitoring requirement. 
MAT-AF implementation significantly increased cardiology 
referral recommendable to avoid the use of antiarrhythmic 
agents when not indicated.  A significant increase in the 
respective documentation of clinical pharmacist 
intervention was observed following MAT implementation.  
The value of MAT-AF implementation was demonstrated in 
the highly significant improvement in documentation of 
interventions by clinical pharmacists in the rehabilitation 
hospital. Documentation is of particular importance in the 
care of the older patient.  Multiple morbidities and 
medication are likely to result in numerous care issues 
which require prioritisation and resolution in a timely 
manner. Documentation is more likely to ascertain that all 
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issues are ultimately communicated with the healthcare 
team. MAT-AF provides a structured system with the 
purpose of guiding pharmacists and facilitating the 
documentation process.  
MAT-AF can be implemented in other care settings for 
older persons including acute, ambulatory and long-term 
care after validation for adaptation to the setting and 
patient population. For a more comprehensive approach in 
the optimisation of drug therapy, it is recommended that 
MATs for other disease states prevalent in older patients 
are developed and implemented.  
A limitation of the study is that MAT-AF criteria which 
incorporate aspects of treatment that are relevant to only a 
few patients resulted in a low applicability when 
considering the entire patient cohort.9 Another limitation is 
that more emphasis may have been given to applying the 
MAT during the study period since the pharmacists were 
aware of the audit being conducted by the researcher 
(Hawthorne effect). 
 
CONCLUSIONS 
Implementation of MAT-AF had a significant impact on 
underprescribing of anticoagulation recommended for the 
prevention of thromboembolism in patients with AF and on 
parameter monitoring to ensure safe use of digoxin. 
Documentation of the care provided by clinical pharmacists 
at the rehabilitation hospital improved as a result of MAT-
AF implementation. 
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